WHO launches global database on sexually transmitted infection prevalence

The World Health Organization (WHO) launched a new global database on 3 July 2026 to track the prevalence of sexually transmitted infections (STIs). The platform, known as the STI Prevalence Atlas, serves as an open-access repository designed to consolidate fragmented data on infection rates across low- and middle-income countries. By gathering published and unpublished studies in one location, the organization aims to provide health authorities and policymakers with the standardized evidence necessary to design targeted prevention strategies and monitor transmission trends.

The launch addresses a longstanding hurdle in global public health: the scarcity of reliable, population-specific Data. Prior to this initiative, information regarding STIs was often scattered across disparate clinical reports, making it difficult for researchers to perform meaningful meta-analyses or for nations to allocate resources effectively. Dr. Tereza Kasaeva, Director of the WHO’s Department for HIV, TB, Hepatitis and STIs, stated that the database serves as a vital step in understanding the burden of these infections across diverse settings.

"By making these data openly accessible, we are equipping countries and partners with the evidence needed to design targeted interventions, strengthen surveillance systems and accelerate progress towards reducing the global impact of STIs."

Media additions

Dr. Tereza Kasaeva, Director of WHO’s Department for HIV, TB, Hepatitis and STIs, via WHO

Database Scope and Quality Standards

As of June 2026, the database contains 2,453 prevalence data points drawn from 766 individual studies. The platform currently focuses on five specific infections: chlamydia, gonorrhoea, syphilis, herpes simplex virus type 2 (HSV-2), and trichomoniasis. To ensure the reliability of the evidence, the Who implemented rigorous inclusion criteria for the studies admitted to the repository:

• Data must have been collected in 2010 or later.
• Studies must have a sample size of at least 100 participants.
• Research must provide clearly defined population groups and sufficient methodological detail.

The Data points are derived from a variety of sources, including household-based surveys, baseline data from intervention studies, case-control studies, and research conducted among specific groups such as adolescents, pregnant women, sex workers, and clinic attendees. According to the WHO, the platform is designed to be dynamic, meaning it will expand over time to include additional pathogens and emerging research findings.

Expert Perspectives and Limitations

While global health officials and organizations like the European AIDS Treatment Group have praised the initiative for providing a centralized, standardized resource, some independent experts warn that the tool's utility remains dependent on the quality of data provided by individual nations. Dr. Aris Harrison, an epidemiologist based in London, noted that the database is only as powerful as the information fed into it. He highlighted a potential vulnerability: if a nation lacks the laboratory infrastructure to identify asymptomatic cases, that country's contribution to the database may remain artificially low.

Further limitations exist regarding the historical scope and coverage of the Atlas. Because the database focuses on studies from 2010 onward, it does not provide a window into long-term trends prior to that period. Additionally, current entries do not include infections such as the human papillomavirus (HPV) or various forms of viral hepatitis, which remain major public health concerns. There is also concern among observers that, because many studies are clinic-based, the data might skew toward higher-risk populations, potentially masking broader community-level transmission rates.

The Context of Co-infection

The urgency of accurate tracking is underscored by the epidemiological link between STIs and other health risks, particularly HIV. Bacterial pathogens—such as those causing syphilis and gonorrhea—induce mucosal inflammation and epithelial disruption, which can increase a host's susceptibility to acquiring HIV. Conversely, HIV-associated immunosuppression can worsen the outcomes of co-existent STIs. These dynamics mean that failure to track and treat common STIs directly hinders efforts to control the spread of other infectious diseases.

What to Watch Next

The WHO intends to manage the STI Prevalence Atlas as an evolving project. Users and researchers should monitor the following developments:

• Data Updates: The organization will continuously incorporate new, peer-reviewed studies and verified national health reports into the dashboard.
• Scope Expansion: Future updates are expected to include a wider array of pathogens beyond the initial five.
• Institutional Feedback: The WHO has opened a channel for researchers and national programs to submit eligible data that meet the study entry criteria to fill remaining geographical or population-specific gaps.

For individuals, health authorities emphasize that the database is a structural and surveillance tool rather than a diagnostic one. Personal health protection continues to rely on consistent preventative behaviors, including the use of barrier protection and routine screening for those who are sexually active, particularly when changing partners or experiencing symptoms.